Back

Efficacy and safety of dapagliflozin in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction (STEMI) in early-hospital period

25 April 2024 (14:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session 2 - Assessing and managing cardiovascular risk in patients with acute cardiac syndromes and stroke Pharmacotherapy Open Access ESC Preventive Cardiology 2024 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Miss Ani Tavaratsyan

Yerevan (Armenia)

6 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor D. Maritsa (London, GB)
Abstract
Presentation thumbnail
Doctor B. Vitola (Riga, LV)
Abstract Slides
Presentation thumbnail
Doctor X. Krasniqi (Pristina, XK)
Abstract Slides
Presentation thumbnail
Doctor R. Gregorio Antunes Coelho (Setubal, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Assessing and managing cardiovascular risk in patients with acute cardiac syndromes and stroke

The Event

Event poster

ESC Preventive Cardiology 2024

25 April 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of dapagliflozin in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction
thumbnail
Congress Presentation
Treatment with SGLT2 inhibitors in the early phase post acute myocardial infarction
thumbnail
Congress Presentation
Efficacy of in-hosptal initiation of dapagliflozin in prevention of heart failure in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources